NCT02287415View on ClinicalTrials.gov

The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

July 31, 2002

Study Completion Date

July 31, 2002

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093

DRUG

Warfarin

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02287415 - The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin | Biotech Hunter | Biotech Hunter